Clinical Trials Logo

Atherosclerotic Vascular Disease clinical trials

View clinical trials related to Atherosclerotic Vascular Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03829046 Completed - Type2 Diabetes Clinical Trials

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Start date: June 3, 2019
Phase: Phase 4
Study type: Interventional

Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition. The eligible subjects will have 6 visits in 13 to 16 weeks and will have Repatha/placebo 140mg subcutaneous every 4 weeks for 3 times since randomization visit, blood tests will be done in each visit to evaluate the effects of evolocumab upon biocellular markers potentially altered by PCSK9 inhibition in a population of type 2 diabetes patients with microvascular dysfunction. Primary Aims: Determine the ACUTE and SHORT-TERM effects of PCSK9 inhibition with evolocumab on biocellular markers of inflammation, immune mediated thrombosis and rheology. The data from this trial will be used to support a clinical trial to assess the role of PCSK9 inhibition in type 2 diabetes patients with cardiac microvascular dysfunction. Secondary Aims: 1. To define the association between PCSK 9 concentrations and immune-related phenotype. 2. To define the association between Lp(a) concentrations, oxidized phospholipids (OxPL), ApoB, biocellular markers of inflammation, tissue factor and immunothrombosis.

NCT ID: NCT02162303 Completed - Clinical trials for Atherosclerotic Vascular Disease

Colchicine in Vascular Inflammation Assessed With PET Imaging

COLPET
Start date: May 2014
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to assess the effects of colchicine on vascular inflammation measured by (FDG)-PET imaging in patients with atherosclerotic vascular disease. This effect will also be measured by soluble plasma biomarkers. Finally, an optional pharmacogenomic investigation will be performed to identify genetic biomarkers of patient response.

NCT ID: NCT00703261 Completed - Clinical trials for Atherosclerotic Vascular Disease

Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the utility of 18Fluorine Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) as a tool to quantify atherosclerotic plaque.